nodes	percent_of_prediction	percent_of_DWPC	metapath
Sumatriptan—ABCB1—esophageal cancer	0.294	1	CbGaD
Sumatriptan—ABCG2—Carboplatin—esophageal cancer	0.0907	0.23	CbGbCtD
Sumatriptan—ABCG2—Cisplatin—esophageal cancer	0.0775	0.196	CbGbCtD
Sumatriptan—SLCO1A2—Methotrexate—esophageal cancer	0.0671	0.17	CbGbCtD
Sumatriptan—SLCO1B1—Methotrexate—esophageal cancer	0.0633	0.16	CbGbCtD
Sumatriptan—ABCG2—Methotrexate—esophageal cancer	0.0503	0.127	CbGbCtD
Sumatriptan—ABCB1—Cisplatin—esophageal cancer	0.0279	0.0707	CbGbCtD
Sumatriptan—ABCB1—Methotrexate—esophageal cancer	0.0181	0.0459	CbGbCtD
Sumatriptan—Melatonin—CALR—esophageal cancer	0.0044	0.558	CrCbGaD
Sumatriptan—HTR3A—vagus nerve—esophageal cancer	0.00363	0.444	CbGeAlD
Sumatriptan—Melatonin—CYP1B1—esophageal cancer	0.00096	0.122	CrCbGaD
Sumatriptan—Eletriptan—CYP2A6—esophageal cancer	0.000854	0.108	CrCbGaD
Sumatriptan—Melatonin—CYP19A1—esophageal cancer	0.000705	0.0893	CrCbGaD
Sumatriptan—Eletriptan—PTGS1—esophageal cancer	0.000654	0.0828	CrCbGaD
Sumatriptan—Skin exfoliation—Capecitabine—esophageal cancer	0.000504	0.00251	CcSEcCtD
Sumatriptan—Fluid retention—Capecitabine—esophageal cancer	0.000501	0.0025	CcSEcCtD
Sumatriptan—MAOA—neck—esophageal cancer	0.000492	0.0603	CbGeAlD
Sumatriptan—Dehydration—Cisplatin—esophageal cancer	0.000483	0.00241	CcSEcCtD
Sumatriptan—Cramp muscle—Cisplatin—esophageal cancer	0.000468	0.00234	CcSEcCtD
Sumatriptan—Speech disorder—Methotrexate—esophageal cancer	0.000457	0.00228	CcSEcCtD
Sumatriptan—Ear pain—Capecitabine—esophageal cancer	0.000449	0.00224	CcSEcCtD
Sumatriptan—Phlebitis—Capecitabine—esophageal cancer	0.000445	0.00222	CcSEcCtD
Sumatriptan—Sleep disorder—Capecitabine—esophageal cancer	0.000442	0.00221	CcSEcCtD
Sumatriptan—Thrombophlebitis—Capecitabine—esophageal cancer	0.000442	0.00221	CcSEcCtD
Sumatriptan—Pancreatitis—Cisplatin—esophageal cancer	0.00044	0.0022	CcSEcCtD
Sumatriptan—Musculoskeletal stiffness—Methotrexate—esophageal cancer	0.000438	0.00219	CcSEcCtD
Sumatriptan—Photosensitivity—Capecitabine—esophageal cancer	0.000436	0.00218	CcSEcCtD
Sumatriptan—Swelling—Capecitabine—esophageal cancer	0.000434	0.00217	CcSEcCtD
Sumatriptan—Gastroenteritis—Capecitabine—esophageal cancer	0.000432	0.00216	CcSEcCtD
Sumatriptan—Abdominal discomfort—Cisplatin—esophageal cancer	0.000431	0.00215	CcSEcCtD
Sumatriptan—Deafness—Capecitabine—esophageal cancer	0.000428	0.00214	CcSEcCtD
Sumatriptan—Pancytopenia—Cisplatin—esophageal cancer	0.000426	0.00213	CcSEcCtD
Sumatriptan—Eye pain—Capecitabine—esophageal cancer	0.000424	0.00212	CcSEcCtD
Sumatriptan—Haemolytic anaemia—Capecitabine—esophageal cancer	0.000424	0.00212	CcSEcCtD
Sumatriptan—Dysarthria—Methotrexate—esophageal cancer	0.000415	0.00207	CcSEcCtD
Sumatriptan—Renal failure acute—Capecitabine—esophageal cancer	0.000415	0.00207	CcSEcCtD
Sumatriptan—HTR3A—digestive system—esophageal cancer	0.000412	0.0505	CbGeAlD
Sumatriptan—Inflammation—Methotrexate—esophageal cancer	0.000405	0.00202	CcSEcCtD
Sumatriptan—Atrial fibrillation—Capecitabine—esophageal cancer	0.000404	0.00202	CcSEcCtD
Sumatriptan—Thirst—Capecitabine—esophageal cancer	0.000402	0.00201	CcSEcCtD
Sumatriptan—Vasculitis—Methotrexate—esophageal cancer	0.000402	0.00201	CcSEcCtD
Sumatriptan—Dermatitis bullous—Capecitabine—esophageal cancer	0.000401	0.002	CcSEcCtD
Sumatriptan—SLCO1B1—digestive system—esophageal cancer	0.0004	0.0489	CbGeAlD
Sumatriptan—Acute coronary syndrome—Cisplatin—esophageal cancer	0.000395	0.00197	CcSEcCtD
Sumatriptan—Arthritis—Capecitabine—esophageal cancer	0.000394	0.00197	CcSEcCtD
Sumatriptan—Pulmonary embolism—Methotrexate—esophageal cancer	0.000393	0.00196	CcSEcCtD
Sumatriptan—Myocardial infarction—Cisplatin—esophageal cancer	0.000393	0.00196	CcSEcCtD
Sumatriptan—Cerebrovascular accident—Capecitabine—esophageal cancer	0.000391	0.00195	CcSEcCtD
Sumatriptan—Conjunctivitis—Cisplatin—esophageal cancer	0.000389	0.00194	CcSEcCtD
Sumatriptan—Cystitis noninfective—Methotrexate—esophageal cancer	0.000384	0.00192	CcSEcCtD
Sumatriptan—Melaena—Methotrexate—esophageal cancer	0.000384	0.00192	CcSEcCtD
Sumatriptan—Osteoarthritis—Capecitabine—esophageal cancer	0.000383	0.00191	CcSEcCtD
Sumatriptan—Gastrointestinal haemorrhage—Capecitabine—esophageal cancer	0.000383	0.00191	CcSEcCtD
Sumatriptan—Diplopia—Capecitabine—esophageal cancer	0.000383	0.00191	CcSEcCtD
Sumatriptan—Cystitis—Methotrexate—esophageal cancer	0.000379	0.00189	CcSEcCtD
Sumatriptan—Migraine—Capecitabine—esophageal cancer	0.000377	0.00188	CcSEcCtD
Sumatriptan—Skin exfoliation—Methotrexate—esophageal cancer	0.000375	0.00187	CcSEcCtD
Sumatriptan—Bradycardia—Cisplatin—esophageal cancer	0.000366	0.00183	CcSEcCtD
Sumatriptan—Dehydration—Capecitabine—esophageal cancer	0.000356	0.00178	CcSEcCtD
Sumatriptan—Bladder pain—Methotrexate—esophageal cancer	0.000355	0.00177	CcSEcCtD
Sumatriptan—Liver function test abnormal—Capecitabine—esophageal cancer	0.000354	0.00177	CcSEcCtD
Sumatriptan—Connective tissue disorder—Cisplatin—esophageal cancer	0.000353	0.00176	CcSEcCtD
Sumatriptan—Visual impairment—Cisplatin—esophageal cancer	0.000346	0.00173	CcSEcCtD
Sumatriptan—HTR3A—lung—esophageal cancer	0.000344	0.0421	CbGeAlD
Sumatriptan—Gastritis—Capecitabine—esophageal cancer	0.000339	0.00169	CcSEcCtD
Sumatriptan—Eye disorder—Cisplatin—esophageal cancer	0.000336	0.00168	CcSEcCtD
Sumatriptan—Tinnitus—Cisplatin—esophageal cancer	0.000335	0.00167	CcSEcCtD
Sumatriptan—Lymphadenopathy—Methotrexate—esophageal cancer	0.000334	0.00167	CcSEcCtD
Sumatriptan—Flushing—Cisplatin—esophageal cancer	0.000334	0.00167	CcSEcCtD
Sumatriptan—Abdominal distension—Capecitabine—esophageal cancer	0.000333	0.00166	CcSEcCtD
Sumatriptan—Influenza—Capecitabine—esophageal cancer	0.000331	0.00165	CcSEcCtD
Sumatriptan—Asthma—Capecitabine—esophageal cancer	0.000331	0.00165	CcSEcCtD
Sumatriptan—Dysphagia—Capecitabine—esophageal cancer	0.000331	0.00165	CcSEcCtD
Sumatriptan—MAOA—bronchus—esophageal cancer	0.00033	0.0404	CbGeAlD
Sumatriptan—Thrombophlebitis—Methotrexate—esophageal cancer	0.000329	0.00164	CcSEcCtD
Sumatriptan—Bronchospasm—Capecitabine—esophageal cancer	0.000326	0.00163	CcSEcCtD
Sumatriptan—SLCO1A2—digestive system—esophageal cancer	0.000325	0.0398	CbGeAlD
Sumatriptan—Photosensitivity—Methotrexate—esophageal cancer	0.000325	0.00162	CcSEcCtD
Sumatriptan—Immune system disorder—Cisplatin—esophageal cancer	0.000325	0.00162	CcSEcCtD
Sumatriptan—Mediastinal disorder—Cisplatin—esophageal cancer	0.000324	0.00162	CcSEcCtD
Sumatriptan—Angina pectoris—Capecitabine—esophageal cancer	0.000322	0.00161	CcSEcCtD
Sumatriptan—Arrhythmia—Cisplatin—esophageal cancer	0.000321	0.0016	CcSEcCtD
Sumatriptan—Bronchitis—Capecitabine—esophageal cancer	0.000318	0.00159	CcSEcCtD
Sumatriptan—Eletriptan—ABCB1—esophageal cancer	0.000318	0.0403	CrCbGaD
Sumatriptan—Abdominal discomfort—Capecitabine—esophageal cancer	0.000317	0.00158	CcSEcCtD
Sumatriptan—Pancytopenia—Capecitabine—esophageal cancer	0.000314	0.00157	CcSEcCtD
Sumatriptan—Erythema—Cisplatin—esophageal cancer	0.000313	0.00156	CcSEcCtD
Sumatriptan—Dysuria—Capecitabine—esophageal cancer	0.00031	0.00155	CcSEcCtD
Sumatriptan—Renal failure acute—Methotrexate—esophageal cancer	0.000309	0.00154	CcSEcCtD
Sumatriptan—Flatulence—Cisplatin—esophageal cancer	0.000308	0.00154	CcSEcCtD
Sumatriptan—Photosensitivity reaction—Capecitabine—esophageal cancer	0.000302	0.00151	CcSEcCtD
Sumatriptan—Weight increased—Capecitabine—esophageal cancer	0.000301	0.0015	CcSEcCtD
Sumatriptan—Visual disturbance—Methotrexate—esophageal cancer	0.000301	0.0015	CcSEcCtD
Sumatriptan—Muscle spasms—Cisplatin—esophageal cancer	0.000301	0.0015	CcSEcCtD
Sumatriptan—Weight decreased—Capecitabine—esophageal cancer	0.0003	0.0015	CcSEcCtD
Sumatriptan—Hyperglycaemia—Capecitabine—esophageal cancer	0.000299	0.00149	CcSEcCtD
Sumatriptan—MAOA—trachea—esophageal cancer	0.000296	0.0363	CbGeAlD
Sumatriptan—Anaphylactoid reaction—Methotrexate—esophageal cancer	0.000295	0.00147	CcSEcCtD
Sumatriptan—Depression—Capecitabine—esophageal cancer	0.000294	0.00147	CcSEcCtD
Sumatriptan—Tremor—Cisplatin—esophageal cancer	0.000293	0.00146	CcSEcCtD
Sumatriptan—Acute coronary syndrome—Capecitabine—esophageal cancer	0.000291	0.00145	CcSEcCtD
Sumatriptan—Cerebrovascular accident—Methotrexate—esophageal cancer	0.000291	0.00145	CcSEcCtD
Sumatriptan—Ill-defined disorder—Cisplatin—esophageal cancer	0.00029	0.00145	CcSEcCtD
Sumatriptan—Myocardial infarction—Capecitabine—esophageal cancer	0.000289	0.00144	CcSEcCtD
Sumatriptan—Anaemia—Cisplatin—esophageal cancer	0.000289	0.00144	CcSEcCtD
Sumatriptan—Conjunctivitis—Capecitabine—esophageal cancer	0.000287	0.00143	CcSEcCtD
Sumatriptan—Osteoarthritis—Methotrexate—esophageal cancer	0.000285	0.00142	CcSEcCtD
Sumatriptan—Malaise—Cisplatin—esophageal cancer	0.000282	0.00141	CcSEcCtD
Sumatriptan—Haematuria—Capecitabine—esophageal cancer	0.000281	0.0014	CcSEcCtD
Sumatriptan—Epistaxis—Capecitabine—esophageal cancer	0.000278	0.00139	CcSEcCtD
Sumatriptan—SLCO1A2—lung—esophageal cancer	0.000272	0.0333	CbGeAlD
Sumatriptan—Convulsion—Cisplatin—esophageal cancer	0.000271	0.00135	CcSEcCtD
Sumatriptan—Bradycardia—Capecitabine—esophageal cancer	0.00027	0.00135	CcSEcCtD
Sumatriptan—Myalgia—Cisplatin—esophageal cancer	0.000266	0.00133	CcSEcCtD
Sumatriptan—Haemoglobin—Capecitabine—esophageal cancer	0.000266	0.00133	CcSEcCtD
Sumatriptan—Anxiety—Cisplatin—esophageal cancer	0.000265	0.00133	CcSEcCtD
Sumatriptan—Haemorrhage—Capecitabine—esophageal cancer	0.000265	0.00132	CcSEcCtD
Sumatriptan—Hypoaesthesia—Capecitabine—esophageal cancer	0.000264	0.00132	CcSEcCtD
Sumatriptan—Liver function test abnormal—Methotrexate—esophageal cancer	0.000263	0.00131	CcSEcCtD
Sumatriptan—Discomfort—Cisplatin—esophageal cancer	0.000263	0.00131	CcSEcCtD
Sumatriptan—Connective tissue disorder—Capecitabine—esophageal cancer	0.00026	0.0013	CcSEcCtD
Sumatriptan—Oedema—Cisplatin—esophageal cancer	0.000255	0.00127	CcSEcCtD
Sumatriptan—Anaphylactic shock—Cisplatin—esophageal cancer	0.000255	0.00127	CcSEcCtD
Sumatriptan—Visual impairment—Capecitabine—esophageal cancer	0.000255	0.00127	CcSEcCtD
Sumatriptan—MAOA—digestive system—esophageal cancer	0.000255	0.0312	CbGeAlD
Sumatriptan—Infection—Cisplatin—esophageal cancer	0.000254	0.00127	CcSEcCtD
Sumatriptan—Nervous system disorder—Cisplatin—esophageal cancer	0.00025	0.00125	CcSEcCtD
Sumatriptan—Thrombocytopenia—Cisplatin—esophageal cancer	0.00025	0.00125	CcSEcCtD
Sumatriptan—Tachycardia—Cisplatin—esophageal cancer	0.000249	0.00124	CcSEcCtD
Sumatriptan—Skin disorder—Cisplatin—esophageal cancer	0.000248	0.00124	CcSEcCtD
Sumatriptan—Eye disorder—Capecitabine—esophageal cancer	0.000248	0.00124	CcSEcCtD
Sumatriptan—Tinnitus—Capecitabine—esophageal cancer	0.000247	0.00123	CcSEcCtD
Sumatriptan—Hyperhidrosis—Cisplatin—esophageal cancer	0.000247	0.00123	CcSEcCtD
Sumatriptan—Asthma—Methotrexate—esophageal cancer	0.000246	0.00123	CcSEcCtD
Sumatriptan—Flushing—Capecitabine—esophageal cancer	0.000246	0.00123	CcSEcCtD
Sumatriptan—Pancreatitis—Methotrexate—esophageal cancer	0.000242	0.00121	CcSEcCtD
Sumatriptan—Angiopathy—Capecitabine—esophageal cancer	0.00024	0.0012	CcSEcCtD
Sumatriptan—Immune system disorder—Capecitabine—esophageal cancer	0.000239	0.00119	CcSEcCtD
Sumatriptan—Mediastinal disorder—Capecitabine—esophageal cancer	0.000239	0.00119	CcSEcCtD
Sumatriptan—Hypotension—Cisplatin—esophageal cancer	0.000239	0.00119	CcSEcCtD
Sumatriptan—Chills—Capecitabine—esophageal cancer	0.000238	0.00119	CcSEcCtD
Sumatriptan—Arrhythmia—Capecitabine—esophageal cancer	0.000237	0.00118	CcSEcCtD
Sumatriptan—Abdominal discomfort—Methotrexate—esophageal cancer	0.000236	0.00118	CcSEcCtD
Sumatriptan—Pancytopenia—Methotrexate—esophageal cancer	0.000234	0.00117	CcSEcCtD
Sumatriptan—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.000233	0.00116	CcSEcCtD
Sumatriptan—Erythema—Capecitabine—esophageal cancer	0.000231	0.00115	CcSEcCtD
Sumatriptan—Dysuria—Methotrexate—esophageal cancer	0.00023	0.00115	CcSEcCtD
Sumatriptan—Paraesthesia—Cisplatin—esophageal cancer	0.000229	0.00114	CcSEcCtD
Sumatriptan—Dyspnoea—Cisplatin—esophageal cancer	0.000228	0.00114	CcSEcCtD
Sumatriptan—Flatulence—Capecitabine—esophageal cancer	0.000227	0.00113	CcSEcCtD
Sumatriptan—Dysgeusia—Capecitabine—esophageal cancer	0.000226	0.00113	CcSEcCtD
Sumatriptan—Photosensitivity reaction—Methotrexate—esophageal cancer	0.000225	0.00112	CcSEcCtD
Sumatriptan—Back pain—Capecitabine—esophageal cancer	0.000223	0.00111	CcSEcCtD
Sumatriptan—Decreased appetite—Cisplatin—esophageal cancer	0.000222	0.00111	CcSEcCtD
Sumatriptan—Muscle spasms—Capecitabine—esophageal cancer	0.000222	0.00111	CcSEcCtD
Sumatriptan—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.00022	0.0011	CcSEcCtD
Sumatriptan—Drowsiness—Methotrexate—esophageal cancer	0.00022	0.0011	CcSEcCtD
Sumatriptan—Depression—Methotrexate—esophageal cancer	0.000219	0.00109	CcSEcCtD
Sumatriptan—Pain—Cisplatin—esophageal cancer	0.000218	0.00109	CcSEcCtD
Sumatriptan—Tremor—Capecitabine—esophageal cancer	0.000216	0.00108	CcSEcCtD
Sumatriptan—Ill-defined disorder—Capecitabine—esophageal cancer	0.000214	0.00107	CcSEcCtD
Sumatriptan—Conjunctivitis—Methotrexate—esophageal cancer	0.000214	0.00107	CcSEcCtD
Sumatriptan—Anaemia—Capecitabine—esophageal cancer	0.000213	0.00106	CcSEcCtD
Sumatriptan—MAOA—lung—esophageal cancer	0.000213	0.0261	CbGeAlD
Sumatriptan—Sweating—Methotrexate—esophageal cancer	0.000211	0.00105	CcSEcCtD
Sumatriptan—Feeling abnormal—Cisplatin—esophageal cancer	0.00021	0.00105	CcSEcCtD
Sumatriptan—DRD2—lung—esophageal cancer	0.00021	0.0258	CbGeAlD
Sumatriptan—Haematuria—Methotrexate—esophageal cancer	0.00021	0.00105	CcSEcCtD
Sumatriptan—Malaise—Capecitabine—esophageal cancer	0.000208	0.00104	CcSEcCtD
Sumatriptan—Epistaxis—Methotrexate—esophageal cancer	0.000207	0.00103	CcSEcCtD
Sumatriptan—Vertigo—Capecitabine—esophageal cancer	0.000207	0.00103	CcSEcCtD
Sumatriptan—Syncope—Capecitabine—esophageal cancer	0.000207	0.00103	CcSEcCtD
Sumatriptan—Palpitations—Capecitabine—esophageal cancer	0.000204	0.00102	CcSEcCtD
Sumatriptan—Loss of consciousness—Capecitabine—esophageal cancer	0.000203	0.00101	CcSEcCtD
Sumatriptan—Body temperature increased—Cisplatin—esophageal cancer	0.000202	0.00101	CcSEcCtD
Sumatriptan—Cough—Capecitabine—esophageal cancer	0.000201	0.001	CcSEcCtD
Sumatriptan—Hypertension—Capecitabine—esophageal cancer	0.000199	0.000994	CcSEcCtD
Sumatriptan—Haemoglobin—Methotrexate—esophageal cancer	0.000198	0.00099	CcSEcCtD
Sumatriptan—Haemorrhage—Methotrexate—esophageal cancer	0.000197	0.000985	CcSEcCtD
Sumatriptan—Chest pain—Capecitabine—esophageal cancer	0.000196	0.00098	CcSEcCtD
Sumatriptan—Myalgia—Capecitabine—esophageal cancer	0.000196	0.00098	CcSEcCtD
Sumatriptan—Arthralgia—Capecitabine—esophageal cancer	0.000196	0.00098	CcSEcCtD
Sumatriptan—Anxiety—Capecitabine—esophageal cancer	0.000196	0.000977	CcSEcCtD
Sumatriptan—Discomfort—Capecitabine—esophageal cancer	0.000194	0.000969	CcSEcCtD
Sumatriptan—Dry mouth—Capecitabine—esophageal cancer	0.000192	0.000959	CcSEcCtD
Sumatriptan—Visual impairment—Methotrexate—esophageal cancer	0.00019	0.000949	CcSEcCtD
Sumatriptan—Confusional state—Capecitabine—esophageal cancer	0.00019	0.000948	CcSEcCtD
Sumatriptan—Oedema—Capecitabine—esophageal cancer	0.000188	0.00094	CcSEcCtD
Sumatriptan—Hypersensitivity—Cisplatin—esophageal cancer	0.000188	0.000939	CcSEcCtD
Sumatriptan—Infection—Capecitabine—esophageal cancer	0.000187	0.000934	CcSEcCtD
Sumatriptan—Shock—Capecitabine—esophageal cancer	0.000185	0.000925	CcSEcCtD
Sumatriptan—Nervous system disorder—Capecitabine—esophageal cancer	0.000185	0.000922	CcSEcCtD
Sumatriptan—ABCG2—lung—esophageal cancer	0.000184	0.0226	CbGeAlD
Sumatriptan—Eye disorder—Methotrexate—esophageal cancer	0.000184	0.00092	CcSEcCtD
Sumatriptan—Thrombocytopenia—Capecitabine—esophageal cancer	0.000184	0.00092	CcSEcCtD
Sumatriptan—Tinnitus—Methotrexate—esophageal cancer	0.000184	0.000918	CcSEcCtD
Sumatriptan—Tachycardia—Capecitabine—esophageal cancer	0.000184	0.000917	CcSEcCtD
Sumatriptan—Asthenia—Cisplatin—esophageal cancer	0.000183	0.000915	CcSEcCtD
Sumatriptan—Skin disorder—Capecitabine—esophageal cancer	0.000183	0.000913	CcSEcCtD
Sumatriptan—Hyperhidrosis—Capecitabine—esophageal cancer	0.000182	0.000908	CcSEcCtD
Sumatriptan—Angiopathy—Methotrexate—esophageal cancer	0.000179	0.000893	CcSEcCtD
Sumatriptan—Immune system disorder—Methotrexate—esophageal cancer	0.000178	0.000889	CcSEcCtD
Sumatriptan—Mediastinal disorder—Methotrexate—esophageal cancer	0.000178	0.000887	CcSEcCtD
Sumatriptan—Chills—Methotrexate—esophageal cancer	0.000177	0.000884	CcSEcCtD
Sumatriptan—Hypotension—Capecitabine—esophageal cancer	0.000176	0.000878	CcSEcCtD
Sumatriptan—Diarrhoea—Cisplatin—esophageal cancer	0.000175	0.000872	CcSEcCtD
Sumatriptan—Erythema—Methotrexate—esophageal cancer	0.000172	0.000857	CcSEcCtD
Sumatriptan—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000172	0.000856	CcSEcCtD
Sumatriptan—Paraesthesia—Capecitabine—esophageal cancer	0.000169	0.000844	CcSEcCtD
Sumatriptan—Dysgeusia—Methotrexate—esophageal cancer	0.000168	0.000839	CcSEcCtD
Sumatriptan—Dyspnoea—Capecitabine—esophageal cancer	0.000168	0.000838	CcSEcCtD
Sumatriptan—Back pain—Methotrexate—esophageal cancer	0.000166	0.000829	CcSEcCtD
Sumatriptan—Decreased appetite—Capecitabine—esophageal cancer	0.000164	0.000817	CcSEcCtD
Sumatriptan—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000163	0.000811	CcSEcCtD
Sumatriptan—Vomiting—Cisplatin—esophageal cancer	0.000162	0.000811	CcSEcCtD
Sumatriptan—Fatigue—Capecitabine—esophageal cancer	0.000162	0.00081	CcSEcCtD
Sumatriptan—Rash—Cisplatin—esophageal cancer	0.000161	0.000804	CcSEcCtD
Sumatriptan—Pain—Capecitabine—esophageal cancer	0.000161	0.000804	CcSEcCtD
Sumatriptan—Constipation—Capecitabine—esophageal cancer	0.000161	0.000804	CcSEcCtD
Sumatriptan—Dermatitis—Cisplatin—esophageal cancer	0.000161	0.000803	CcSEcCtD
Sumatriptan—Ill-defined disorder—Methotrexate—esophageal cancer	0.000159	0.000795	CcSEcCtD
Sumatriptan—Anaemia—Methotrexate—esophageal cancer	0.000159	0.000792	CcSEcCtD
Sumatriptan—Feeling abnormal—Capecitabine—esophageal cancer	0.000155	0.000774	CcSEcCtD
Sumatriptan—Malaise—Methotrexate—esophageal cancer	0.000155	0.000773	CcSEcCtD
Sumatriptan—Vertigo—Methotrexate—esophageal cancer	0.000154	0.00077	CcSEcCtD
Sumatriptan—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000154	0.000768	CcSEcCtD
Sumatriptan—Nausea—Cisplatin—esophageal cancer	0.000152	0.000757	CcSEcCtD
Sumatriptan—Cough—Methotrexate—esophageal cancer	0.00015	0.000748	CcSEcCtD
Sumatriptan—Urticaria—Capecitabine—esophageal cancer	0.00015	0.000747	CcSEcCtD
Sumatriptan—Abdominal pain—Capecitabine—esophageal cancer	0.000149	0.000743	CcSEcCtD
Sumatriptan—Body temperature increased—Capecitabine—esophageal cancer	0.000149	0.000743	CcSEcCtD
Sumatriptan—Convulsion—Methotrexate—esophageal cancer	0.000149	0.000743	CcSEcCtD
Sumatriptan—Arthralgia—Methotrexate—esophageal cancer	0.000146	0.00073	CcSEcCtD
Sumatriptan—Myalgia—Methotrexate—esophageal cancer	0.000146	0.00073	CcSEcCtD
Sumatriptan—Chest pain—Methotrexate—esophageal cancer	0.000146	0.00073	CcSEcCtD
Sumatriptan—MAOA—lymph node—esophageal cancer	0.000146	0.0178	CbGeAlD
Sumatriptan—Discomfort—Methotrexate—esophageal cancer	0.000144	0.000721	CcSEcCtD
Sumatriptan—ABCB1—epithelium—esophageal cancer	0.000143	0.0175	CbGeAlD
Sumatriptan—Confusional state—Methotrexate—esophageal cancer	0.000141	0.000705	CcSEcCtD
Sumatriptan—Anaphylactic shock—Methotrexate—esophageal cancer	0.00014	0.0007	CcSEcCtD
Sumatriptan—Infection—Methotrexate—esophageal cancer	0.000139	0.000695	CcSEcCtD
Sumatriptan—Hypersensitivity—Capecitabine—esophageal cancer	0.000139	0.000692	CcSEcCtD
Sumatriptan—Nervous system disorder—Methotrexate—esophageal cancer	0.000137	0.000686	CcSEcCtD
Sumatriptan—Thrombocytopenia—Methotrexate—esophageal cancer	0.000137	0.000685	CcSEcCtD
Sumatriptan—Skin disorder—Methotrexate—esophageal cancer	0.000136	0.00068	CcSEcCtD
Sumatriptan—Hyperhidrosis—Methotrexate—esophageal cancer	0.000135	0.000676	CcSEcCtD
Sumatriptan—Asthenia—Capecitabine—esophageal cancer	0.000135	0.000674	CcSEcCtD
Sumatriptan—Pruritus—Capecitabine—esophageal cancer	0.000133	0.000665	CcSEcCtD
Sumatriptan—Hypotension—Methotrexate—esophageal cancer	0.000131	0.000654	CcSEcCtD
Sumatriptan—Diarrhoea—Capecitabine—esophageal cancer	0.000129	0.000643	CcSEcCtD
Sumatriptan—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000128	0.000637	CcSEcCtD
Sumatriptan—ABCB1—trachea—esophageal cancer	0.000127	0.0155	CbGeAlD
Sumatriptan—ABCG2—lymph node—esophageal cancer	0.000126	0.0155	CbGeAlD
Sumatriptan—Paraesthesia—Methotrexate—esophageal cancer	0.000126	0.000628	CcSEcCtD
Sumatriptan—Dyspnoea—Methotrexate—esophageal cancer	0.000125	0.000624	CcSEcCtD
Sumatriptan—Somnolence—Methotrexate—esophageal cancer	0.000125	0.000622	CcSEcCtD
Sumatriptan—Dizziness—Capecitabine—esophageal cancer	0.000124	0.000621	CcSEcCtD
Sumatriptan—Decreased appetite—Methotrexate—esophageal cancer	0.000122	0.000608	CcSEcCtD
Sumatriptan—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000121	0.000604	CcSEcCtD
Sumatriptan—Fatigue—Methotrexate—esophageal cancer	0.000121	0.000603	CcSEcCtD
Sumatriptan—Pain—Methotrexate—esophageal cancer	0.00012	0.000598	CcSEcCtD
Sumatriptan—Vomiting—Capecitabine—esophageal cancer	0.00012	0.000598	CcSEcCtD
Sumatriptan—Rash—Capecitabine—esophageal cancer	0.000119	0.000593	CcSEcCtD
Sumatriptan—Dermatitis—Capecitabine—esophageal cancer	0.000119	0.000592	CcSEcCtD
Sumatriptan—Headache—Capecitabine—esophageal cancer	0.000118	0.000589	CcSEcCtD
Sumatriptan—Feeling abnormal—Methotrexate—esophageal cancer	0.000115	0.000576	CcSEcCtD
Sumatriptan—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000115	0.000572	CcSEcCtD
Sumatriptan—Nausea—Capecitabine—esophageal cancer	0.000112	0.000558	CcSEcCtD
Sumatriptan—Urticaria—Methotrexate—esophageal cancer	0.000111	0.000556	CcSEcCtD
Sumatriptan—Abdominal pain—Methotrexate—esophageal cancer	0.000111	0.000553	CcSEcCtD
Sumatriptan—Body temperature increased—Methotrexate—esophageal cancer	0.000111	0.000553	CcSEcCtD
Sumatriptan—ABCB1—digestive system—esophageal cancer	0.000109	0.0133	CbGeAlD
Sumatriptan—Hypersensitivity—Methotrexate—esophageal cancer	0.000103	0.000515	CcSEcCtD
Sumatriptan—Asthenia—Methotrexate—esophageal cancer	0.000101	0.000502	CcSEcCtD
Sumatriptan—Pruritus—Methotrexate—esophageal cancer	9.92e-05	0.000495	CcSEcCtD
Sumatriptan—Diarrhoea—Methotrexate—esophageal cancer	9.59e-05	0.000479	CcSEcCtD
Sumatriptan—Dizziness—Methotrexate—esophageal cancer	9.27e-05	0.000463	CcSEcCtD
Sumatriptan—ABCB1—lung—esophageal cancer	9.1e-05	0.0111	CbGeAlD
Sumatriptan—Vomiting—Methotrexate—esophageal cancer	8.91e-05	0.000445	CcSEcCtD
Sumatriptan—Rash—Methotrexate—esophageal cancer	8.84e-05	0.000441	CcSEcCtD
Sumatriptan—Dermatitis—Methotrexate—esophageal cancer	8.83e-05	0.000441	CcSEcCtD
Sumatriptan—Headache—Methotrexate—esophageal cancer	8.78e-05	0.000438	CcSEcCtD
Sumatriptan—Nausea—Methotrexate—esophageal cancer	8.32e-05	0.000416	CcSEcCtD
Sumatriptan—ABCB1—lymph node—esophageal cancer	6.22e-05	0.00762	CbGeAlD
Sumatriptan—SLCO1B1—Metabolism—ALDH2—esophageal cancer	3.15e-05	0.000333	CbGpPWpGaD
Sumatriptan—ABCG2—Metabolism—GNG7—esophageal cancer	3.11e-05	0.000329	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—CTNNA1—esophageal cancer	3.08e-05	0.000326	CbGpPWpGaD
Sumatriptan—DRD2—Signaling by GPCR—SST—esophageal cancer	3.07e-05	0.000324	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—CXCL2—esophageal cancer	3.06e-05	0.000324	CbGpPWpGaD
Sumatriptan—ABCB1—Integrated Pancreatic Cancer Pathway—BCL2—esophageal cancer	3.05e-05	0.000323	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—ELMO1—esophageal cancer	3.05e-05	0.000322	CbGpPWpGaD
Sumatriptan—MAOA—Metabolism—PTGS1—esophageal cancer	3.04e-05	0.000322	CbGpPWpGaD
Sumatriptan—MAOA—Metabolism—ENO1—esophageal cancer	3.04e-05	0.000322	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—CTNNA1—esophageal cancer	3.01e-05	0.000319	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—CA1—esophageal cancer	3e-05	0.000318	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—SLC10A2—esophageal cancer	3e-05	0.000318	CbGpPWpGaD
Sumatriptan—MAOA—Metabolism—PSME1—esophageal cancer	3e-05	0.000317	CbGpPWpGaD
Sumatriptan—MAOA—Metabolism—PSME2—esophageal cancer	3e-05	0.000317	CbGpPWpGaD
Sumatriptan—SLCO1B1—Metabolism—GSTT1—esophageal cancer	3e-05	0.000317	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—CXCL2—esophageal cancer	3e-05	0.000317	CbGpPWpGaD
Sumatriptan—DRD2—Signaling by GPCR—GHRL—esophageal cancer	2.99e-05	0.000316	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—PFN1—esophageal cancer	2.98e-05	0.000315	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—AKAP13—esophageal cancer	2.98e-05	0.000315	CbGpPWpGaD
Sumatriptan—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—esophageal cancer	2.96e-05	0.000313	CbGpPWpGaD
Sumatriptan—SLCO1B1—Metabolism—CYP2A6—esophageal cancer	2.96e-05	0.000313	CbGpPWpGaD
Sumatriptan—SLCO1B1—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	2.95e-05	0.000312	CbGpPWpGaD
Sumatriptan—ABCG2—Metabolism—ALDH2—esophageal cancer	2.92e-05	0.000309	CbGpPWpGaD
Sumatriptan—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—esophageal cancer	2.9e-05	0.000307	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—PSME2—esophageal cancer	2.86e-05	0.000302	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—PSME1—esophageal cancer	2.86e-05	0.000302	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—ANXA1—esophageal cancer	2.84e-05	0.000301	CbGpPWpGaD
Sumatriptan—SLCO1A2—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	2.83e-05	0.000299	CbGpPWpGaD
Sumatriptan—SLCO1B1—Metabolism—ENO1—esophageal cancer	2.81e-05	0.000297	CbGpPWpGaD
Sumatriptan—SLCO1B1—Metabolism—PTGS1—esophageal cancer	2.81e-05	0.000297	CbGpPWpGaD
Sumatriptan—SLCO1B1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	2.81e-05	0.000297	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—PSME1—esophageal cancer	2.8e-05	0.000296	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—PSME2—esophageal cancer	2.8e-05	0.000296	CbGpPWpGaD
Sumatriptan—SLCO1A2—Metabolism—CYP1B1—esophageal cancer	2.79e-05	0.000295	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—ANXA1—esophageal cancer	2.78e-05	0.000295	CbGpPWpGaD
Sumatriptan—ABCG2—Metabolism—GSTT1—esophageal cancer	2.78e-05	0.000294	CbGpPWpGaD
Sumatriptan—SLCO1B1—Metabolism—PSME2—esophageal cancer	2.77e-05	0.000293	CbGpPWpGaD
Sumatriptan—SLCO1B1—Metabolism—PSME1—esophageal cancer	2.77e-05	0.000293	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—SST—esophageal cancer	2.77e-05	0.000293	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—HIST1H2BM—esophageal cancer	2.75e-05	0.000291	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—CA2—esophageal cancer	2.75e-05	0.000291	CbGpPWpGaD
Sumatriptan—ABCG2—Metabolism—CYP2A6—esophageal cancer	2.74e-05	0.00029	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—PDE4D—esophageal cancer	2.72e-05	0.000288	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—SST—esophageal cancer	2.71e-05	0.000287	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—GHRL—esophageal cancer	2.7e-05	0.000285	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—NOTCH3—esophageal cancer	2.7e-05	0.000285	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—ELMO1—esophageal cancer	2.67e-05	0.000283	CbGpPWpGaD
Sumatriptan—DRD2—Circadian rythm related genes—TP53—esophageal cancer	2.67e-05	0.000283	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—FBXW7—esophageal cancer	2.65e-05	0.000281	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—NOTCH3—esophageal cancer	2.64e-05	0.000279	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—GHRL—esophageal cancer	2.64e-05	0.000279	CbGpPWpGaD
Sumatriptan—SLCO1A2—Metabolism—CYP19A1—esophageal cancer	2.63e-05	0.000278	CbGpPWpGaD
Sumatriptan—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—esophageal cancer	2.62e-05	0.000277	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—AKAP13—esophageal cancer	2.61e-05	0.000277	CbGpPWpGaD
Sumatriptan—ABCG2—Metabolism—PTGS1—esophageal cancer	2.6e-05	0.000275	CbGpPWpGaD
Sumatriptan—ABCG2—Metabolism—ENO1—esophageal cancer	2.6e-05	0.000275	CbGpPWpGaD
Sumatriptan—ABCG2—Transmembrane transport of small molecules—CREBBP—esophageal cancer	2.6e-05	0.000275	CbGpPWpGaD
Sumatriptan—HTR1F—Signaling Pathways—HIF1A—esophageal cancer	2.6e-05	0.000275	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—FBXW7—esophageal cancer	2.6e-05	0.000275	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—GNG7—esophageal cancer	2.59e-05	0.000274	CbGpPWpGaD
Sumatriptan—MAOA—Metabolism—CYP1B1—esophageal cancer	2.59e-05	0.000274	CbGpPWpGaD
Sumatriptan—ABCG2—Metabolism—PSME2—esophageal cancer	2.56e-05	0.000271	CbGpPWpGaD
Sumatriptan—ABCG2—Metabolism—PSME1—esophageal cancer	2.56e-05	0.000271	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—ADH7—esophageal cancer	2.55e-05	0.00027	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—PLCE1—esophageal cancer	2.55e-05	0.00027	CbGpPWpGaD
Sumatriptan—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—esophageal cancer	2.53e-05	0.000268	CbGpPWpGaD
Sumatriptan—HTR1F—Signaling Pathways—KDR—esophageal cancer	2.48e-05	0.000263	CbGpPWpGaD
Sumatriptan—MAOA—Metabolism—CYP19A1—esophageal cancer	2.43e-05	0.000257	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—XIAP—esophageal cancer	2.43e-05	0.000257	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—NOTCH2—esophageal cancer	2.42e-05	0.000256	CbGpPWpGaD
Sumatriptan—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	2.42e-05	0.000256	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—HIST1H2BM—esophageal cancer	2.41e-05	0.000255	CbGpPWpGaD
Sumatriptan—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—esophageal cancer	2.41e-05	0.000255	CbGpPWpGaD
Sumatriptan—SLCO1A2—Metabolism—HMOX1—esophageal cancer	2.4e-05	0.000253	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—PDE4D—esophageal cancer	2.39e-05	0.000253	CbGpPWpGaD
Sumatriptan—SLCO1B1—Metabolism—CYP1B1—esophageal cancer	2.39e-05	0.000253	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—NOTCH2—esophageal cancer	2.37e-05	0.000251	CbGpPWpGaD
Sumatriptan—SLCO1A2—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	2.35e-05	0.000249	CbGpPWpGaD
Sumatriptan—HTR1F—Signaling Pathways—NOTCH1—esophageal cancer	2.34e-05	0.000248	CbGpPWpGaD
Sumatriptan—SLCO1A2—Metabolism—ABCB1—esophageal cancer	2.3e-05	0.000243	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—CTNNA1—esophageal cancer	2.3e-05	0.000243	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—CXCL2—esophageal cancer	2.28e-05	0.000241	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—GNG7—esophageal cancer	2.27e-05	0.000241	CbGpPWpGaD
Sumatriptan—SLCO1B1—Metabolism—CYP19A1—esophageal cancer	2.25e-05	0.000238	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—ADH1B—esophageal cancer	2.24e-05	0.000237	CbGpPWpGaD
Sumatriptan—MAOA—Metabolism—HMOX1—esophageal cancer	2.22e-05	0.000235	CbGpPWpGaD
Sumatriptan—ABCG2—Metabolism—CYP1B1—esophageal cancer	2.21e-05	0.000234	CbGpPWpGaD
Sumatriptan—ABCB1—Transmembrane transport of small molecules—HMOX1—esophageal cancer	2.19e-05	0.000232	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—TGFBR2—esophageal cancer	2.15e-05	0.000227	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—TYMP—esophageal cancer	2.14e-05	0.000226	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—PSME1—esophageal cancer	2.13e-05	0.000226	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—PSME2—esophageal cancer	2.13e-05	0.000226	CbGpPWpGaD
Sumatriptan—MAOA—Metabolism—ABCB1—esophageal cancer	2.13e-05	0.000225	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—XIAP—esophageal cancer	2.13e-05	0.000225	CbGpPWpGaD
Sumatriptan—HTR1F—Signaling Pathways—CREBBP—esophageal cancer	2.12e-05	0.000225	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—ANXA1—esophageal cancer	2.12e-05	0.000224	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—TGFBR2—esophageal cancer	2.1e-05	0.000222	CbGpPWpGaD
Sumatriptan—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—esophageal cancer	2.1e-05	0.000222	CbGpPWpGaD
Sumatriptan—HTR1F—Signaling by GPCR—EGFR—esophageal cancer	2.09e-05	0.000221	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—CYP26A1—esophageal cancer	2.08e-05	0.00022	CbGpPWpGaD
Sumatriptan—ABCG2—Metabolism—CYP19A1—esophageal cancer	2.08e-05	0.00022	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—SST—esophageal cancer	2.06e-05	0.000218	CbGpPWpGaD
Sumatriptan—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—esophageal cancer	2.05e-05	0.000217	CbGpPWpGaD
Sumatriptan—SLCO1B1—Metabolism—HMOX1—esophageal cancer	2.05e-05	0.000217	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—SMAD4—esophageal cancer	2.03e-05	0.000215	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—ALOX15—esophageal cancer	2.03e-05	0.000215	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—CTNNA1—esophageal cancer	2.02e-05	0.000213	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—GHRL—esophageal cancer	2.01e-05	0.000213	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—NOTCH3—esophageal cancer	2.01e-05	0.000213	CbGpPWpGaD
Sumatriptan—SLCO1B1—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	2.01e-05	0.000213	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—CXCL2—esophageal cancer	2e-05	0.000212	CbGpPWpGaD
Sumatriptan—HTR1F—GPCR downstream signaling—PIK3CA—esophageal cancer	1.99e-05	0.000211	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—SMAD4—esophageal cancer	1.99e-05	0.00021	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—FBXW7—esophageal cancer	1.98e-05	0.000209	CbGpPWpGaD
Sumatriptan—SLCO1B1—Metabolism—ABCB1—esophageal cancer	1.97e-05	0.000208	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—TPI1—esophageal cancer	1.94e-05	0.000205	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—GSTO1—esophageal cancer	1.94e-05	0.000205	CbGpPWpGaD
Sumatriptan—HTR1F—Signaling Pathways—NOS3—esophageal cancer	1.9e-05	0.000201	CbGpPWpGaD
Sumatriptan—ABCG2—Metabolism—HMOX1—esophageal cancer	1.9e-05	0.000201	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—PSME1—esophageal cancer	1.87e-05	0.000198	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—PSME2—esophageal cancer	1.87e-05	0.000198	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—ANXA1—esophageal cancer	1.86e-05	0.000197	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—ALDOB—esophageal cancer	1.86e-05	0.000196	CbGpPWpGaD
Sumatriptan—ABCG2—Metabolism—ABCB1—esophageal cancer	1.82e-05	0.000193	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—SST—esophageal cancer	1.81e-05	0.000192	CbGpPWpGaD
Sumatriptan—HTR1F—Signaling by GPCR—PIK3CA—esophageal cancer	1.81e-05	0.000191	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—NOTCH2—esophageal cancer	1.8e-05	0.000191	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—GAPDH—esophageal cancer	1.79e-05	0.000189	CbGpPWpGaD
Sumatriptan—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	1.78e-05	0.000189	CbGpPWpGaD
Sumatriptan—HTR1F—Signaling Pathways—ERBB2—esophageal cancer	1.78e-05	0.000188	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—CRABP1—esophageal cancer	1.77e-05	0.000187	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—GHRL—esophageal cancer	1.77e-05	0.000187	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—NOTCH3—esophageal cancer	1.77e-05	0.000187	CbGpPWpGaD
Sumatriptan—SLCO1A2—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.74e-05	0.000184	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—FBXW7—esophageal cancer	1.74e-05	0.000184	CbGpPWpGaD
Sumatriptan—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	1.72e-05	0.000182	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—GNG7—esophageal cancer	1.68e-05	0.000178	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—HIF1A—esophageal cancer	1.66e-05	0.000176	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—HIF1A—esophageal cancer	1.63e-05	0.000172	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—TGFBR2—esophageal cancer	1.6e-05	0.000169	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—KDR—esophageal cancer	1.59e-05	0.000168	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—NOTCH2—esophageal cancer	1.58e-05	0.000168	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—ALDH2—esophageal cancer	1.58e-05	0.000167	CbGpPWpGaD
Sumatriptan—HTR1F—Signaling Pathways—CCND1—esophageal cancer	1.57e-05	0.000166	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—KDR—esophageal cancer	1.56e-05	0.000165	CbGpPWpGaD
Sumatriptan—SLCO1A2—Metabolism—CREBBP—esophageal cancer	1.54e-05	0.000163	CbGpPWpGaD
Sumatriptan—HTR1F—Signaling Pathways—CDKN1A—esophageal cancer	1.52e-05	0.000161	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—SMAD4—esophageal cancer	1.51e-05	0.00016	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—GSTT1—esophageal cancer	1.5e-05	0.000159	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—NOTCH1—esophageal cancer	1.5e-05	0.000158	CbGpPWpGaD
Sumatriptan—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.49e-05	0.000157	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—CYP2A6—esophageal cancer	1.48e-05	0.000157	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—NOTCH1—esophageal cancer	1.47e-05	0.000155	CbGpPWpGaD
Sumatriptan—HTR1F—Signaling Pathways—EP300—esophageal cancer	1.45e-05	0.000153	CbGpPWpGaD
Sumatriptan—MAOA—Metabolism—CREBBP—esophageal cancer	1.42e-05	0.000151	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—ENO1—esophageal cancer	1.41e-05	0.000149	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—PTGS1—esophageal cancer	1.41e-05	0.000149	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—TGFBR2—esophageal cancer	1.4e-05	0.000149	CbGpPWpGaD
Sumatriptan—ABCB1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	1.4e-05	0.000149	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—PSME2—esophageal cancer	1.39e-05	0.000147	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—PSME1—esophageal cancer	1.39e-05	0.000147	CbGpPWpGaD
Sumatriptan—SLCO1A2—Metabolism—NOS3—esophageal cancer	1.38e-05	0.000146	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—CREBBP—esophageal cancer	1.36e-05	0.000144	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling by GPCR—EGFR—esophageal cancer	1.33e-05	0.000141	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—SMAD4—esophageal cancer	1.33e-05	0.000141	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—CREBBP—esophageal cancer	1.33e-05	0.000141	CbGpPWpGaD
Sumatriptan—SLCO1B1—Metabolism—CREBBP—esophageal cancer	1.31e-05	0.000139	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling by GPCR—EGFR—esophageal cancer	1.31e-05	0.000138	CbGpPWpGaD
Sumatriptan—MAOA—Metabolism—NOS3—esophageal cancer	1.28e-05	0.000135	CbGpPWpGaD
Sumatriptan—HTR1D—GPCR downstream signaling—PIK3CA—esophageal cancer	1.27e-05	0.000135	CbGpPWpGaD
Sumatriptan—HTR1F—Signaling Pathways—MYC—esophageal cancer	1.26e-05	0.000133	CbGpPWpGaD
Sumatriptan—SLCO1A2—Metabolism—PTGS2—esophageal cancer	1.26e-05	0.000133	CbGpPWpGaD
Sumatriptan—HTR1B—GPCR downstream signaling—PIK3CA—esophageal cancer	1.25e-05	0.000132	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—HIF1A—esophageal cancer	1.24e-05	0.000131	CbGpPWpGaD
Sumatriptan—HTR1F—Signaling Pathways—EGFR—esophageal cancer	1.23e-05	0.00013	CbGpPWpGaD
Sumatriptan—ABCG2—Metabolism—CREBBP—esophageal cancer	1.22e-05	0.000129	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—NOS3—esophageal cancer	1.22e-05	0.000129	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—CYP1B1—esophageal cancer	1.2e-05	0.000126	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—NOS3—esophageal cancer	1.19e-05	0.000126	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—KDR—esophageal cancer	1.19e-05	0.000125	CbGpPWpGaD
Sumatriptan—SLCO1B1—Metabolism—NOS3—esophageal cancer	1.18e-05	0.000124	CbGpPWpGaD
Sumatriptan—MAOA—Metabolism—PTGS2—esophageal cancer	1.17e-05	0.000123	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling by GPCR—PIK3CA—esophageal cancer	1.16e-05	0.000122	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—ERBB2—esophageal cancer	1.14e-05	0.00012	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling by GPCR—PIK3CA—esophageal cancer	1.13e-05	0.00012	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—CYP19A1—esophageal cancer	1.12e-05	0.000119	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—NOTCH1—esophageal cancer	1.12e-05	0.000118	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—ERBB2—esophageal cancer	1.11e-05	0.000118	CbGpPWpGaD
Sumatriptan—ABCG2—Metabolism—NOS3—esophageal cancer	1.09e-05	0.000115	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—HIF1A—esophageal cancer	1.09e-05	0.000115	CbGpPWpGaD
Sumatriptan—SLCO1B1—Metabolism—PTGS2—esophageal cancer	1.08e-05	0.000114	CbGpPWpGaD
Sumatriptan—HTR1F—Signaling Pathways—PIK3CA—esophageal cancer	1.07e-05	0.000113	CbGpPWpGaD
Sumatriptan—SLCO1A2—Metabolism—EP300—esophageal cancer	1.05e-05	0.000111	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—KDR—esophageal cancer	1.04e-05	0.00011	CbGpPWpGaD
Sumatriptan—HTR1F—Signaling Pathways—TP53—esophageal cancer	1.03e-05	0.000109	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—HMOX1—esophageal cancer	1.03e-05	0.000109	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—CREBBP—esophageal cancer	1.01e-05	0.000107	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—CCND1—esophageal cancer	1e-05	0.000106	CbGpPWpGaD
Sumatriptan—ABCG2—Metabolism—PTGS2—esophageal cancer	9.97e-06	0.000105	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling by GPCR—EGFR—esophageal cancer	9.95e-06	0.000105	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—CCND1—esophageal cancer	9.83e-06	0.000104	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—NOTCH1—esophageal cancer	9.8e-06	0.000104	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—CDKN1A—esophageal cancer	9.71e-06	0.000103	CbGpPWpGaD
Sumatriptan—MAOA—Metabolism—EP300—esophageal cancer	9.7e-06	0.000103	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—CDKN1A—esophageal cancer	9.51e-06	0.000101	CbGpPWpGaD
Sumatriptan—HTR1A—GPCR downstream signaling—PIK3CA—esophageal cancer	9.51e-06	0.000101	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—EP300—esophageal cancer	9.24e-06	9.78e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—NOS3—esophageal cancer	9.06e-06	9.59e-05	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—EP300—esophageal cancer	9.05e-06	9.57e-05	CbGpPWpGaD
Sumatriptan—SLCO1B1—Metabolism—EP300—esophageal cancer	8.95e-06	9.47e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—CREBBP—esophageal cancer	8.89e-06	9.4e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling by GPCR—EGFR—esophageal cancer	8.73e-06	9.24e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling by GPCR—PIK3CA—esophageal cancer	8.63e-06	9.13e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—ERBB2—esophageal cancer	8.48e-06	8.97e-05	CbGpPWpGaD
Sumatriptan—DRD2—GPCR downstream signaling—PIK3CA—esophageal cancer	8.35e-06	8.83e-05	CbGpPWpGaD
Sumatriptan—ABCG2—Metabolism—EP300—esophageal cancer	8.29e-06	8.77e-05	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—MYC—esophageal cancer	8.05e-06	8.52e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—NOS3—esophageal cancer	7.96e-06	8.42e-05	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—MYC—esophageal cancer	7.89e-06	8.34e-05	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—EGFR—esophageal cancer	7.88e-06	8.33e-05	CbGpPWpGaD
Sumatriptan—SLCO1A2—Metabolism—PIK3CA—esophageal cancer	7.74e-06	8.19e-05	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—EGFR—esophageal cancer	7.71e-06	8.16e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling by GPCR—PIK3CA—esophageal cancer	7.58e-06	8.02e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—CCND1—esophageal cancer	7.49e-06	7.92e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—ERBB2—esophageal cancer	7.44e-06	7.87e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—CDKN1A—esophageal cancer	7.25e-06	7.67e-05	CbGpPWpGaD
Sumatriptan—MAOA—Metabolism—PIK3CA—esophageal cancer	7.18e-06	7.59e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—EP300—esophageal cancer	6.89e-06	7.29e-05	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—PIK3CA—esophageal cancer	6.84e-06	7.23e-05	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—PIK3CA—esophageal cancer	6.69e-06	7.08e-05	CbGpPWpGaD
Sumatriptan—SLCO1B1—Metabolism—PIK3CA—esophageal cancer	6.62e-06	7.01e-05	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—TP53—esophageal cancer	6.61e-06	7e-05	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—CREBBP—esophageal cancer	6.58e-06	6.96e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—CCND1—esophageal cancer	6.58e-06	6.96e-05	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—TP53—esophageal cancer	6.48e-06	6.85e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—CDKN1A—esophageal cancer	6.36e-06	6.73e-05	CbGpPWpGaD
Sumatriptan—ABCG2—Metabolism—PIK3CA—esophageal cancer	6.13e-06	6.49e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—EP300—esophageal cancer	6.05e-06	6.4e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—MYC—esophageal cancer	6.01e-06	6.36e-05	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—NOS3—esophageal cancer	5.89e-06	6.23e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—EGFR—esophageal cancer	5.88e-06	6.22e-05	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—PTGS2—esophageal cancer	5.39e-06	5.7e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—MYC—esophageal cancer	5.27e-06	5.58e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—EGFR—esophageal cancer	5.16e-06	5.46e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—PIK3CA—esophageal cancer	5.1e-06	5.4e-05	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—TP53—esophageal cancer	4.93e-06	5.22e-05	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—EP300—esophageal cancer	4.48e-06	4.74e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—PIK3CA—esophageal cancer	4.48e-06	4.74e-05	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—TP53—esophageal cancer	4.33e-06	4.58e-05	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—PIK3CA—esophageal cancer	3.31e-06	3.51e-05	CbGpPWpGaD
